A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
NCT04983264
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
GBT021601
Sponsor
Pfizer